Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
about
CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.Unleashing the therapeutic potential of human kallikrein-related serine proteases.Enhancement of glioma-specific immunity in mice by "NOBEL", an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide.
P2860
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
@ast
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
@en
type
label
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
@ast
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
@en
prefLabel
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
@ast
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
@en
P2860
P356
P1433
P1476
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
@en
P2093
James L Gulley
Ravi A Madan
P2860
P356
10.2217/IMT.10.77
P577
2011-01-01T00:00:00Z